Serotonin Levels in Atopic Dermatitis Patients

NCT03471819 | Unknown

• 1 other identifier: SLAD
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease of unknown aetiology. Global prevalence rates range from 1%-20%.AD is often worsened by stress and anxiety.Plasma levels of 5-HT were found to be positively correlated with the disease severity.

Conditions

Dermatologic Disease

Keywords

Atopic Dermatitis; serotonin

Outcome Measures

Primary Outcomes (1)

• SCORAD

  Scoring Atopic Dermatitis "SCORAD" is a clinical tool for assessing the severity of AD as objectively as possible. It includes: A: Spread B: Intensity C: Subjective symptoms

  one month

Secondary Outcomes (1)

• Beck's depression score (Arabic version)

  one month

Study Arms (2)

Patients withf Atopic Dermatitis

Diagnosis is based upon American Academy of Dermatology recommendations for Diagnostic Criteria 2014.

Diagnostic Test: Serum serotonin level

healthy volunteers

Normal individuals not complaining of any dermatological diseases

Diagnostic Test: Serum serotonin level

Interventions

Serum serotonin level DIAGNOSTIC_TEST

blood sample will be obtained to evaluate serum level of serotonin

Patients withf Atopic Dermatitis; healthy volunteers

Eligibility Criteria

• Age: 2 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

50 patients with the clinical diagnosis of AD and 30 age and sex-matched apparently healthy volunteers will be included in this study

You may qualify if:

• All patients with the clinical diagnosis of AD.
• Age more than 2

You may not qualify if:

• Age less than 2 years.
• Any concomitant systemic or dermatological disease.
• Patients on any topical or systemic treatment during the past one month.
• Uncooperative patients.
• Refusal to participate

Sponsors & Collaborators

• Assiut University: lead

Related Publications (3)

• Abdel-Hafez K, Abdel-Aty MA, Hofny ER. Prevalence of skin diseases in rural areas of Assiut Governorate, Upper Egypt. Int J Dermatol. 2003 Nov;42(11):887-92. doi: 10.1046/j.1365-4362.2003.01936.x.

  PMID: 14636205 BACKGROUND

• Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S28-S36. doi: 10.1016/j.jaad.2017.12.022.

  PMID: 29471919 BACKGROUND

• Afzal R, Shim WS. Glucosylsphingosine Activates Serotonin Receptor 2a and 2b: Implication of a Novel Itch Signaling Pathway. Biomol Ther (Seoul). 2017 Sep 1;25(5):497-503. doi: 10.4062/biomolther.2016.207.

  PMID: 28208011 BACKGROUND

MeSH Terms

Conditions

Skin Diseases; Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin and Connective Tissue Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Dalia A Negm, Lecturer

  Assiut University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Eman R Hofny, Professor

CONTACT

01005298992; e_riad@yahoo.com

Ayman M Mahran, Lecturer

CONTACT

01009948311; aymanderma@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: March 14, 2018
• First Posted: March 21, 2018
• Study Start: April 1, 2018
• Primary Completion: March 31, 2019
• Study Completion: April 30, 2019
• Last Updated: March 22, 2018

Record last verified: 2018-03